CO63 Real-World Comparative Effectiveness of the First COVID-19 mRNA Booster, mRNA-1273 Versus BNT162b2, Among US Medicare Fee-for-Service Non-Immunocompromised Beneficiaries Aged 65 and Older
Jun 1, 2024, 00:00 AM
10.1016/j.jval.2024.03.151
https://www.valueinhealthjournal.com/article/S1098-3015(24)00266-3/fulltext
Section Title :
Section Order :
10921
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00266-3&doi=10.1016/j.jval.2024.03.151